| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/06/2004 | WO2004037314A2 Patch and kit containing delayed-type hypersensitivity inducer |
| 05/06/2004 | WO2004037311A2 Device and methods for sequential, regional delivery of multiple cytotoxic agents |
| 05/06/2004 | WO2004037293A1 Stabilized composition |
| 05/06/2004 | WO2004037292A1 Colon cleansing compositions |
| 05/06/2004 | WO2004037291A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | WO2004037290A1 Sustained release composition for oral administration of drugs |
| 05/06/2004 | WO2004037289A2 Novel injectable depot formulations |
| 05/06/2004 | WO2004037280A1 Angiogenesis inducer |
| 05/06/2004 | WO2004037275A1 Bile acid conjugates and particles formed therewith |
| 05/06/2004 | WO2004037271A1 Cyclooxygenase regulation with ps liposomes |
| 05/06/2004 | WO2004037270A1 Cyclooxygenase regulation with pg liposomes |
| 05/06/2004 | WO2004037267A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 05/06/2004 | WO2004037264A1 Water-soluble meloxicam granulates |
| 05/06/2004 | WO2004037263A1 Pharmaceutical compositions of ganciclovir |
| 05/06/2004 | WO2004037262A2 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 05/06/2004 | WO2004037260A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037259A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037232A1 Targeted delivery |
| 05/06/2004 | WO2004037231A1 Capsule and film-forming composition comprising gum arabic |
| 05/06/2004 | WO2004037230A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037229A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | WO2004037228A1 Sustained release compositions containing alfuzosin |
| 05/06/2004 | WO2004037227A1 Salmeterol superfine formulation |
| 05/06/2004 | WO2004037226A2 Pharmaceutical compositions containing venlafaxine |
| 05/06/2004 | WO2004037225A2 Cosmetic and pharmaceutical foam |
| 05/06/2004 | WO2004037224A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 05/06/2004 | WO2004037223A2 Liposome-forming compositions |
| 05/06/2004 | WO2004037222A2 Sustained-release tramadol formulations with 24-hour efficacy |
| 05/06/2004 | WO2004037203A2 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | WO2004037201A2 Topical skin care composition |
| 05/06/2004 | WO2004037190A2 Modified release compositions of milnacipran |
| 05/06/2004 | WO2004037187A2 Metal-containing materials, compositions and methods |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004030652A3 Dosage form having an inner core and at least two coating layers |
| 05/06/2004 | WO2004024133B1 Novel pharmaceutical formulations of modafinil |
| 05/06/2004 | WO2004017918A3 Method of preparing dry powder inhalation compositions |
| 05/06/2004 | WO2004013605A3 Nanoparticles comprising a mixed monolayer for specific ligand binding |
| 05/06/2004 | WO2004009053A3 Oral delivery system containing a gel matrix and liposomes |
| 05/06/2004 | WO2004001002A3 Novel anticholesterol compositions and method for using same |
| 05/06/2004 | WO2003103389A3 Cryopreservation of haptenized tumor cells |
| 05/06/2004 | WO2003088923A3 Methods of treating ileus |
| 05/06/2004 | WO2003070154A3 Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same |
| 05/06/2004 | WO2003066712A8 Method for preparation of block copolymeric nanoparticles |
| 05/06/2004 | WO2003051304A3 Bioadhesive drug delivery system with enhanced gastric retention |
| 05/06/2004 | WO2003032957A9 Methods for hermetically sealing microchip reservoir devices |
| 05/06/2004 | WO2003026625A9 Modified release dosage forms |
| 05/06/2004 | WO2003026624A9 Modified release dosage forms |
| 05/06/2004 | WO2003020219B1 Aerosolized decongestants for the treatment of sinusitis |
| 05/06/2004 | WO2003009817A9 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 05/06/2004 | WO2002091995A8 Method to induce neovascular formation and tissue regeneration |
| 05/06/2004 | WO2002056881A8 Fenofibrate tablets |
| 05/06/2004 | WO2002022150A3 Medicament containing activated antithrombin iii |
| 05/06/2004 | US20040087894 Devices, systems and methods for patient infusion |
| 05/06/2004 | US20040087888 Pharmaceutical compounding systems and methods and information management system for same |
| 05/06/2004 | US20040087777 Humanized antibodies that recognize beta amyloid peptide |
| 05/06/2004 | US20040087669 Homogenizing starch and swelling agents; extrusion using rotary dies |
| 05/06/2004 | US20040087656 Controlling particle size; efficient pharmokinetics profile; surface stabilizer; bioadhesive |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087612 Topical administering in aqueous solution |
| 05/06/2004 | US20040087605 N-but-3-enyl norbuprenorphine and methods of use |
| 05/06/2004 | US20040087602 Topical viricide; photostabilizer for inorganic oxide pigment; 2-bromovinyl deoxyuridine mixtures |
| 05/06/2004 | US20040087578 Pharmaceutical compositions containing carvedilol and hydrochlorothiazide |
| 05/06/2004 | US20040087567 Anticancer agents; particularly liver cancer |
| 05/06/2004 | US20040087564 Delivery composition and method |
| 05/06/2004 | US20040087557 Treating muscle wasting with selective androgen receptor modulators |
| 05/06/2004 | US20040087550 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 05/06/2004 | US20040087544 .1-10,000 mg/mL of a glycosaminoglycan, .001-5% of osmolarity-correcting agent, .0001-30% of a preservative of paraben, benzyl alchool, chlorbutanol, chlorcresol, benzetoin chloride, benzalconium chloride and solvents; ph 4.5-8.5 |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087529 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/06/2004 | US20040087528 Delivering plasmid vector encoding HERG (A561V) (human ether-a-go-go related gene) protein to cells afflicted with re-entrant atrial flutter mediated cardiac arrhythmia |
| 05/06/2004 | US20040087520 Compositions and methods for delivery of therapeutic agents |
| 05/06/2004 | US20040087507 Containing amino acid; long term storage stability |
| 05/06/2004 | US20040087494 Glycopeptide carboxy-saccharide derivatives |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087482 Microparticle-drug conjugates for biological targeting |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |
| 05/06/2004 | US20040087024 Comprises polyethylenimine coupled to cyclodextrins; for cell transfection; kits |
| 05/06/2004 | US20040087015 Polysaccharides; antidiabetic agents; Parkinson's disease |
| 05/06/2004 | US20040087013 Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| 05/06/2004 | US20040086603 Edible inks for ink-jet printing on edible substrates |
| 05/06/2004 | US20040086582 Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
| 05/06/2004 | US20040086579 Dietary supplement comprising parthenolide |
| 05/06/2004 | US20040086578 Physiologically acceptable aqueous solutions and methods for their use |
| 05/06/2004 | US20040086574 Iron-free multi-vitamin/mineral/antioxidant formulation, designed to optimize health and wellness, minimize oxidative stress, and normalize homocysteine levels |
| 05/06/2004 | US20040086572 Providing formulation comprising magnetic particles, having associated therapeutic agent, and using a magnetic field to move magnetic particles to desired location within eye |
| 05/06/2004 | US20040086571 For therapy of dyslipidemia and dyslipoproteinemia |
| 05/06/2004 | US20040086570 Controlled-release dosage; therapy |
| 05/06/2004 | US20040086569 Active agent delivery systems, medical devices, and methods |
| 05/06/2004 | US20040086567 Dissolution |
| 05/06/2004 | US20040086566 High loading dose of a highly water soluble active agent |
| 05/06/2004 | US20040086565 Orally administering to once prior to sleep a dosage formulation comprising a biologically inert pellet having a drug layer, an outer rate controlling layer |
| 05/06/2004 | US20040086564 Dosage forms containing stabilized choline and method for preparing same |
| 05/06/2004 | US20040086563 To control the release of pharmaceutically active substances so that they can be administered in a few daily doses, ideally in a single daily dose |
| 05/06/2004 | US20040086562 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 05/06/2004 | US20040086561 For preventing oral abuse of an oral opioid formulation |
| 05/06/2004 | US20040086559 Pharmaceutical tablet comprising paroextine mesylate |
| 05/06/2004 | US20040086558 Non-cationic liposomes which are either neutral or have a negative charge not containing peptides and which encapsulate a nucleotide sequence |
| 05/06/2004 | US20040086557 Polyethylene glycol coated Pokeweed Mitogen and Recombinant Interleukin II |
| 05/06/2004 | US20040086556 Transdermal and topical administration of local anesthetic agents using basic enhancers |